Do the three SGLT2 inhibitors differ in cardiovascular outcomes and safety?
Study examines the comparative cardiovascular efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes.
Register for free access or login.
Canadian Healthcare Network is an independent online community for Canadian healthcare professionals in medicine and pharmacy. It is the online home of the Medical Post and Pharmacy Practice + Business.
Membership is free and allows doctors, pharmacists, nurses and many others to get the latest breaking news, updates on clinical guidelines and read (and even write) commentary from your healthcare peers.
